JoÃ£o N Moreira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8831963/publications.pdf

Version: 2024-02-01

85	3,231	136740	155451
papers	citations	32 h-index	55 g-index

85	85	85	4816
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin. Drug Delivery and Translational Research, 2022, 12, 629-646.	3.0	6
2	Antagonist G-targeted liposomes for improved delivery of anticancer drugs in small cell lung carcinoma. International Journal of Pharmaceutics, 2022, 612, 121380.	2.6	8
3	Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 61-77.	2.0	2
4	New advances in exosome-based targeted drug delivery systems. Critical Reviews in Oncology/Hematology, 2022, 172, 103628.	2.0	47
5	Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer. Cancers, 2022, 14, 2217.	1.7	7
6	Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis. Pharmaceuticals, 2021, 14, 60.	1.7	31
7	In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. Advances in Experimental Medicine and Biology, 2021, 1295, 271-299.	0.8	5
8	Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of inÂvivo studies. Acta Pharmaceutica Sinica B, 2021, 11, 925-940.	5.7	113
9	GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure. Nano Today, 2021, 37, 101095.	6.2	15
10	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 180.	3.5	27
11	The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. Cancers, 2021, 13, 3052.	1.7	7
12	In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). Pharmaceuticals, 2021, 14, 711.	1.7	37
13	Current challenges and emerging opportunities of CAR-T cell therapies. Journal of Controlled Release, 2020, 319, 246-261.	4.8	78
14	Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102206.	1.7	44
15	Application of the Quality-by-Design (QbD) Approach to Improve the Nose-to-Brain Delivery of Diazepam-Loaded Nanostructured Lipid Carriers (NLCs). Proceedings (mdpi), 2020, 78, .	0.2	1
16	Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. Drug Discovery Today, 2019, 24, 1985-2001.	3.2	52
17	Hormones, Blood Products, and Therapeutic Enzymes. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 115-153.	0.6	1
18	Insights on the Formulation of Recombinant Proteins. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 23-54.	0.6	3

#	Article	IF	Citations
19	Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy. , 2019, , .		0
20	Meeting the needs of breast cancer: A nucleolinâ€™s perspective. Critical Reviews in Oncology/Hematology, 2018, 125, 89-101.	2.0	32
21	Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 835-847.	1.7	17
22	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathology and Oncology Research, 2018, 24, 701-716.	0.9	17
23	Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 171-211.	0.2	0
24	Lipid-Based Nanosystems for the Delivery of siRNA: Challenges and Trends. , 2018, , 495-515.		0
25	Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies. Scientific Reports, 2018, 8, 7450.	1.6	12
26	Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Experimental Cell Research, 2018, 370, 68-77.	1.2	24
27	Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles. Current Pharmaceutical Design, 2018, 23, 6563-6572.	0.9	4
28	Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. Journal of Controlled Release, 2017, 258, 182-195.	4.8	79
29	The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors. Critical Reviews in Oncology/Hematology, 2017, 113, 111-121.	2.0	30
30	Dual release of a hydrophilic and a hydrophobic osteogenic factor from a single liposome. RSC Advances, 2016, 6, 114599-114612.	1.7	6
31	Safety profile of the intravenous administration of brain-targeted stable nucleic acid lipid particles. Data in Brief, 2016, 6, 700-705.	0.5	11
32	Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials, 2016, 82, 124-137.	5.7	86
33	Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model. PLoS ONE, 2016, 11, e0165817.	1.1	31
34	On the use of dexamethasone-loaded liposomes to induce the osteogenic differentiation of human mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 1056-1066.	1.3	33
35	Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials, 2015, 69, 76-88.	5.7	73
36	Antibacterial activity of chitosan nanofiber meshes with liposomes immobilized releasing gentamicin. Acta Biomaterialia, 2015, 18, 196-205.	4.1	154

#	Article	IF	Citations
37	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. Current Topics in Medicinal Chemistry, 2015, 16, 291-313.	1.0	2
38	Bridging cancer biology and the patients' needs with nanotechnology-based approaches. Cancer Treatment Reviews, 2014, 40, 626-635.	3.4	40
39	Immobilization of bioactive factor-loaded liposomes on the surface of electrospun nanofibers targeting tissue engineering. Biomaterials Science, 2014, 2, 1195-1209.	2.6	54
40	Instructive Nanofibrous Scaffold Comprising Runt-Related Transcription Factor 2 Gene Delivery for Bone Tissue Engineering. ACS Nano, 2014, 8, 8082-8094.	7.3	81
41	Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy. Procedia in Vaccinology, 2014, 8, 62-67.	0.4	6
42	Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. Journal of Controlled Release, 2014, 196, 122-131.	4.8	34
43	Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cellular and Molecular Life Sciences, 2014, 71, 1417-1438.	2.4	25
44	Abstract 3003: Targeting nucleolin: A potential strategy to overcome stroma-mediated bevacizumab resistance in lung cancer. , 2014, , .		0
45	Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. Molecular Therapy - Nucleic Acids, 2013, 2, e100.	2.3	83
46	MRI Tracking of Macrophages Labeled with Glucan Particles Entrapping a Water Insoluble Paramagnetic Gd-Based Agent. Molecular Imaging and Biology, 2013, 15, 307-315.	1.3	16
47	Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nanomedicine, 2013, 8, 1397-1413.	1.7	23
48	Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 356-364.	2.0	27
49	Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin. Current Gene Therapy, 2013, 13, 189-201.	0.9	7
50	Development, Characterization and In Vitro Evaluation of Single or Co-Loaded Imatinib Mesylate Liposomal Formulations. Journal of Nanoscience and Nanotechnology, 2012, 12, 2891-2900.	0.9	2
51	Nature-inspired particles as carriers for multimodal molecular imaging applications. , 2012, , .		0
52	Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges. Accounts of Chemical Research, 2012, 45, 1163-1171.	7.6	199
53	Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Research and Treatment, 2012, 133, 61-73.	1.1	54
54	Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. International Journal of Pharmaceutics, 2012, 434, 9-19.	2.6	45

#	Article	IF	Citations
55	Yeast cell wall particles: a promising class of nature-inspired microcarriers for multimodal imaging. Chemical Communications, 2011, 47, 10635.	2.2	31
56	Selective Cytotoxicity of Oxysterols through Structural Modulation on Rings A and B. Synthesis, in Vitro Evaluation, and SAR. Journal of Medicinal Chemistry, 2011, 54, 6375-6393.	2.9	46
57	Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. Cancer Chemotherapy and Pharmacology, 2011, 67, 275-284.	1.1	17
58	Supramolecular protamine/Gd-loaded liposomes adducts as relaxometric protease responsive probes. Bioorganic and Medicinal Chemistry, 2011, 19, 1131-1135.	1.4	14
59	Liposomal imatinibâ€“mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate, 2011, 71, 81-90.	1.2	31
60	Abstract 4444: Targeted delivery of siRNAs to tumor cells and the tumor microenvironment. , 2011, , .		0
61	Abstract C233: Limiting tumor invasion with multifunctional nanoparticle targeting the tumor microenvironment.. , 2011, , .		0
62	Coâ€encapsulation of antiâ€BCRâ€ABL siRNA and imatinib mesylate in transferrin receptorâ€targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnology and Bioengineering, 2010, 107, 884-893.	1.7	47
63	Synthesis and structureâ€“activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid. Bioorganic and Medicinal Chemistry, 2010, 18, 4385-4396.	1.4	63
64	In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability. Brazilian Journal of Medical and Biological Research, 2010, 43, 1001-1009.	0.7	6
65	Sterols as Anticancer Agents: Synthesis of Ring-B Oxygenated Steroids, Cytotoxic Profile, and Comprehensive SAR Analysis. Journal of Medicinal Chemistry, 2010, 53, 7632-7638.	2.9	64
66	Transferrin Receptor-Targeted Liposomes Encapsulating anti-BCR-ABL siRNA or asODN for Chronic Myeloid Leukemia Treatment. Bioconjugate Chemistry, 2010, 21, 157-168.	1.8	82
67	Design of peptide-targeted liposomes containing nucleic acids. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 433-441.	1.4	36
68	Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemotherapy and Pharmacology, 2009, 64, 445-454.	1.1	26
69	Efficient Chemoenzymatic Synthesis, Cytotoxic Evaluation, and SAR of Epoxysterols. Journal of Medicinal Chemistry, 2009, 52, 4007-4019.	2.9	30
70	Chapter 14 Targeted Lipoplexes for siRNA Delivery. Methods in Enzymology, 2009, 465, 267-287.	0.4	14
71	Abstract A129: Targeted delivery of therapeutics to tumor cells and the tumor microenvironment. , 2009, , .		1
72	Simultaneous evaluation of viability and Bclâ€2 in smallâ€cell lung cancer. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1165-1172.	1.1	10

#	Article	IF	Citations
73	Synthesis and Photoluminescence of ZnS Quantum Dots. Journal of Nanoscience and Nanotechnology, 2008, 8, 1312-1315.	0.9	39
74	Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality. Reviews on Recent Clinical Trials, 2006, 1, 217-235.	0.4	47
75	Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 359-366.	2.0	49
76	Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer. Brazilian Journal of Medical and Biological Research, 2004, 37, 1185-1192.	0.7	9
77	On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews, 2004, 56, 947-965.	6.6	440
78	Technology evaluation: LErafAON, NeoPharm. Current Opinion in Molecular Therapeutics, 2003, 5, 547-52.	2.8	4
79	ADVENTURES IN TARGETING. Journal of Liposome Research, 2002, 12, 5-12.	1.5	56
80	Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharmaceutical Research, 2002, 19, 265-269.	1.7	127
81	A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1514, 303-317.	1.4	40
82	Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1515, 167-176.	1.4	88
83	Carboplatin liposomes coated with O-palmitoylpullulan: In vitro characterization. International Journal of Pharmaceutics, 1997, 147, 153-164.	2.6	12
84	Evaluation of in vitro stability of large unilamellar liposomes coated with a modified polysaccharide (O-palmitoylpullulan). Journal of Materials Science: Materials in Medicine, 1996, 7, 301-303.	1.7	11
85	Quimioterapia combinada no tratamento do cancro: princÃpios e estratÃ©gias nanotecnolÃ³gicas de entrega de fÃ¡rmacos. , 0, , 675-700.		0